We’re welcoming 2023 by sharing the milestones we accomplished in 2022!
A timeline of highlights from our 36th year:
Awakn Life Sciences Partnership
Awakn Life Sciences and MAPS to Explore Partnership for Treatment of Alcohol Use Disorder in Europe
MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD
MDMA-Assisted Therapy for PTSD
MAPS Completes Enrollment for Phase 3 Trial of MDMA-Assisted Therapy for PTSD
Board of Directors Appointment
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations
Psychedelics: Chemicals, Consciousness, and Creativity
Psychedelics: Chemicals, Consciousness, and Creativity features Rick Doblin, Ph.D., MAPS Founder
Conference on Psychedelic Research 2022
MAPS Speaks at Interdisciplinary Conference on Psychedelic Research 2022
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
MDMA Therapy Training
MDMA Therapy Training Program Trains 766 Therapists
Thank you to all our supporters for making 2022 an amazing year! Next year, don't miss Psychedelic Science 2023, the largest psychedelic gathering in history, presented by MAPS from June 19-23 in Denver, Colorado!
Help Us Deliver Global Healing
Every dollar that MAPS has raised for psychedelic research and therapy been donated by people like you. Your tax-deductible contributions are what allow MAPS to pursue the important and challenging work of psychedelic research, drug policy reform, public education, health equity, and harm reduction initiatives.
Thanks for your contribution to MAPS!
Your tax-deductible contribution supports psychedelic science research, drug policy reform, public education, harm reduction, peer support, and our general operations.